Drugs / GSK1562902A
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT01323946 | Apr 2011 → Jun 2012 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00506350 | Aug 2007 → Oct 2009 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00502593 | Jul 2007 → Dec 2009 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00397215 | Nov 2006 → Sep 2009 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT00866580 | May 2010 → Jul 2011 | influenza | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 3 | NCT00812981 | Nov 2008 → Jun 2009 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00652743 | Mar 2008 → Jun 2011 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00449670 | Mar → Jul 2007 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00319098 | May 2006 → Jan 2007 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK 1562902A | “Two doses of the GSK1562902A adjuvanted split virus vaccine, administered intramuscularly into the deltoid region of the non-dominant arm at Day 0 and Day 21.” NCT00449670 ↗8“Male and female subjects aged 18 or over received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm.” NCT00319098 ↗ “Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine GSK 1562902A.” NCT00866580 ↗ |
| Known as | 1562902A | “two doses of the new-processed (NP) 1562902A vaccine” NCT00812981 ↗1“GSK's candidate influenza vaccine 1562902A” NCT00866580 ↗ |
| Modality | Vaccine | “pandemic influenza candidate vaccine” NCT00397215 ↗ |
| Route | Intramuscular | “received two intramuscular doses of the GSK1562902A study vaccine” NCT00319098 ↗ |